GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (STU:YP1B) » Definitions » Net Loan

Immutep (STU:YP1B) Net Loan


View and export this data going back to 2009. Start your Free Trial

What is Immutep Net Loan?

Net Loan only applies to banks and insurance companies.


Immutep Business Description

Traded in Other Exchanges
Address
264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.